Kirby McInerney LLP is investigating potential claims against the Board of Directors of BioClinica, Inc. (“BioClinica” or the “Company”) (NASDAQ: BIOC) related to the proposed acquisition of the Company by JLL Partners, Inc., a private equity firm. Under the terms of the agreement, JLL Partners will commence a cash tender offer to purchase all of BioClinica’s common stock for $7.25 per share, valuing the Company at approximately $123 million.
The investigation concerns whether the BioClinica Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $7.25 per share consideration adequately values BioClinica shares. The offer price represents a 19% premium to the closing price of BioClinica shares the day prior to the announcement. At least one analyst has a price target for the Company’s stock of $9.00 per share, 24% above the offer price.
If you are a BioClinica shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at email@example.com, or by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
J. Brandon Walker, Esq.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here